您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
发布时间: 2019 - 03 - 11
点击次数: 0
所属职位: 总裁兼首席执行官
所属公司: 依生生物制药有限公司
个人简介:
具有20多年美国生物医药和美国资本市场的从业经验原美国罗氏制药(Roche)主任科学家 (美国新泽西州)原 Kamunting Street 对冲基金高级分析师和投资经理(美国纽约)原 Mehta Partners 对冲基金高级医疗分析师(美国纽约)美国纽约大学 Stern 商学院金融和财务 MBA美国加利福尼亚大学生物化学博士美国特许金融分析师(CFA), 美国注册会计师(AICPA)
发布时间: 2019 - 03 - 12
点击次数: 0
所属职位: 疫苗中心负责人
所属公司: UNICEF-United Nations International Children's Emergency Fund
个人简介:
Heather Deehan is the Chief, Vaccine Centre, UNICEF Supply Division, overseeing the supply and procurement of vaccines on behalf of over 100 countries to increase access for approximately 45% of the world’s children. UNICEF supplies vaccine to support national routine immunization programs, campaigns, outbreak response, and is the procurement agency for Gavi, the Vaccine Alliance in addition to the lead for supply in support of the Global Polio Eradication Initiative. Before joining UNICEF, Heather was the Chief, Vaccine Preventable Diseases at the Public Health Agency of Canada, leading a team of epidemiologists in surveillance and outbreak response activities of vaccine preventable diseases in Canada, and surveillance of Acute Flaccid Paralysis, measles and rubella contributing to global strategies to eradicate and eliminate disease. Heather has also worked in pandemic preparedness and response, immunization surveillance activities including automated identification of vaccine products for inventory management at the national level (bar coding), direct service delivery of immunization and other health care services as both a public health nurse and practical nurse in Canada.
发布时间: 2019 - 03 - 18
点击次数: 0
所属职位: 首席运营官
所属公司: 武汉博沃生物科技有限公司
个人简介:
Dr. Chong obtained his BSc (1978) and PhD (1983) from the department of Biochemistry in the University of Alberta, Edmonton, Canada. He was trained as a protein chemist and specialized in peptide synthesis for protein structure and function studies. After 2 years as a MRC postdoctoral in the University of British Columbia, Dr. Chong moved to Toronto and had spent 15 years at Connaught Laboratory Limited (now called Sanofi Pasteur) in human vaccine research and development. During his tenure there as a Research Scientist (July/1985) and Director (July/1994), Dr. Chong had developed two human vaccines, ProHibit against H. influenzae type b (Hib) and the component pertussis vaccine, and also took a synthetic peptide-based HIV vaccine to Phase I clinical trials in 1994.  Dr. Chong moved to New York in 2000 and joined United Biomedical Inc. (UBI) where he helped developing a peptide-based animal Foot-Mouth Disease vaccine for pig that is currently licensed in China. Dr. Chong was recruited and joined NHRI in 2003 and as the founder established the Vaccine Research and Development Center (VRDC). To facilitate and implement the Taiwanese Government Vaccine R&D, Self-Manufacturing and Supply strategic plans, Dr. Chong had developed and took both cell-based H5N1 flu vaccine and EV71 vaccine to phase I clinical trials. In March 2018, Dr. Chong joined BravoVax, Wuhan. Dr. Chong has authored over 200 original research articles and has over 80 patents filed and/or granted.
发布时间: 2019 - 03 - 28
点击次数: 0
所属职位: 会长 / 副会长
所属公司: 中国兽药协会 / 中国兽医协会
个人简介:
才学鹏,男,博士,研究员,中国兽药协会会长,中国兽医协会副会长,中国微生物学会兽医微生物学专业委员会主任委员,中国畜牧兽医学会家畜寄生虫分会副理事长,中国畜牧兽医学会口蹄疫病学分会副理事长。先后被评为“国家百千万”人才工程第一、二层次人选、农业部有突出贡献的中青年专家、农业部“神农计划”首批提名人、中国农业科学院“一级岗位杰出人才”,享受国务院政府特殊津贴。长期从事预防兽医学研究,在我国重大动物疫病特别是在OIE规定的动物一类疫病口蹄疫、小反刍兽疫和人畜共患寄生虫病防控研究方面成绩显著、贡献突出,获得兽医寄生虫学终身成就奖。先后主持国家科技攻关、支撑计划、“973”课题、“863”计划、国家重点研发计划、国家自然科学基金项目、国家社会公益性研究重大项目、农业部重点课题、甘肃省农业生物技术项目等多项科研项目,获得国家科学技术进步奖二等奖1项、省部级科学技术进步奖一等奖1项、二等奖5项、三等奖2项、发明专利33项。培养硕士、博士116名;发表论文300余篇,其中SCI论文73篇。领导成立兽医行业第一个产业技术创新联盟,实现产学研一体化;领导组建家畜疫病病原生物学国家重点实验室,提升了病原学的研究水平;领导建成国家口蹄疫参考实验室、兰州口蹄疫疫苗生产工程项目,实现了口蹄疫研究和生产条件的现代化,产生显著的经济和社会效益,为遏制口蹄疫的暴发和流行发挥了重要作用。
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务